Tangential Flow Filtration Membrane Patents: Leaders & Trends 2026
Tangential Flow Filtration Membrane Selection Patents
29.7% concentration at the top. The five leading assignees hold 719 of 2,424 records in scope, a narrow band for a field this operationally broad. Annual filings rose from 68 in 2017 to a peak of 183 in 2020, then eased toward 96 in 2024 — a 30% pullback from the 2021 level of 138. Counts for 2025 and 2026 are still incomplete because publication typically lags filing by roughly 18 months; treat the tail of the trend as a floor, not a ceiling.
- 1REGENERON PHARMACEUTICALS INC7.6%
- 2EMD MILLIPORE CORP6.4%
- 3GENENTECH INC5.6%
- 4NORTHWEST BIOTHERAPEUTICS INC5.3%
- 5PALL CORP4.7%
See the full tangential flow filtration membrane selection analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Questions practitioners ask about this landscape
Who holds the most patents on tangential flow filtration membrane selection?
The leading assignee in this dataset holds 184 of the 2,424 records in scope, ahead of a fifth-place company at 115. The top five combined account for 719 records, or 29.7% of the field, and the top ten reach 43.2%. That still leaves a substantial long tail of companies with only a handful of filings each, so a single-company view of the leaderboard understates how fragmented the rest of the field is.
Is patent filing in tangential flow filtration membrane technology growing or slowing?
Filing activity peaked in 2020 at 183 records and pulled back to 96 by 2024, a 30% decline from the 2021 level of 138. That is the most recent year the dataset treats as complete, because patent publication typically lags actual filing by around 18 months. Figures for 2025 and 2026 will keep rising as those applications publish, so it is premature to call the trend still falling based on the newest years alone.
What patent classes cover tangential flow filtration membrane selection?
The dominant classification is B01D, covering separation processes including filtration, which appears on 65.3% of the 2,424 records in scope. C12N (microorganisms and genetic engineering) follows at 46.3%, and C07K (peptides and proteins) at 28.9%, reflecting how closely membrane hardware claims are tied to biologics and cell-therapy applications in this corpus. Because a single record can carry several IPC classes, these percentages are not mutually exclusive and should not be summed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Tangential Flow Filtration Membrane Selection covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.